SCM
KERX

Sterling Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Sterling Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-18,878
Closed -$267K – 996
2014
Q4 		$267K Sell
18,878
-6,474
-26% -$100K ﹤0.01% 855
2014
Q3 		$349K Buy
+25,352
New +$388K ﹤0.01% 795

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sterling Capital Management's KERX Position: Q1 2015 in Review

Sterling Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2015, closing a stake of 18,878 shares — an estimated $267K sold.

Sterling Capital Management first reported a position in KERX in Q3 2014 and held it in 2 quarters. The position peaked at $349K in Q3 2014. 157 funds tracked by Wall St. Rank hold KERX as of Q1 2015.

  • Sterling Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • Sterling Capital Management sold 18,878 Keryx Biopharmaceuticals Inc shares in Q1 2015, an estimated $267K.
  • Sterling Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q3 2014 and held it in 2 quarters.
  • Sterling Capital Management's Keryx Biopharmaceuticals Inc position peaked at $349K in Q3 2014.
  • 157 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2015.

Based on Sterling Capital Management's 13F filing for Q1 2015, filed 19 May 2015.